Furthermore, all 3 prostate cancer cell lines treated with sorafenib, Apo2L/TRAIL, mapatumumab or lexatumumab for 72 hours, showed similar results by crystal violet staining (Figure S2). This evidence concerns the gene TNFSF10 and prostate cancer.